Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Tezepelumab for Bronchiolitis Obliterans Syndrome (BOS)

Allogeneic hematopoietic stem cell transplantation (HSCT) is burdened with a high morbidity and mortality rates. Graft versus host disease (GVHD) is the clinical manifestation of an immune conflict.

Official registry: https://clinicaltrials.gov/study/NCT07771855 · Hopital Foch · enrollment listed as 36

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Tezepelumab. The registry lists allocation as na. Allogeneic hematopoietic stem cell transplantation (HSCT) is burdened with a high morbidity and mortality rates.

They plan to enroll about 36 people at 6 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients

Interventions: Tezepelumab

Primary outcome (registry wording): Change in the annualized number of bronchial exacerbations

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Adult recipients, minimum age 18
  • Recipient of an allogeneic bone marrow or haematopoietic stem cell transplant
  • At more than 3 years after the date of the transplantation
  • Presenting an exacerbation profile: 2 or more moderate to severe bronchial exacerbations in the previous 12 months
  • On optimal inhaled therapy comprising at least one long-acting bronchodilator and one inhaled corticosteroid for at least three months
  • Stable dose of systemic immunosuppressive regimen for the last 4 weeks
  • Being covered by a national health insurance

Public study contact (from the registry)

Yahya DEBZA

+33 1 46 25 36 42

y.debza@hopital-foch.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

6 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Role of Genetic Factors in the Development of Lung Disease

This study is designed to measure the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease. The study will focus on defining the distribution of abnormal genes responsible for processes directly involved in different diseases affecting the lungs of patients and healthy volunteers.

NCT00001532 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)

FAQ about this NCT record

Is NCT07771855 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07771855?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07771855?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary